Preventing levodopa-induced dyskinesias

Annals of Neurology

Volumn 47, Issue 4 SUPPL. 1, 2000, Pages

  Olanow, C Warren ^a   Obeso, Jose A ^b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NAVARRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

4,6,6A,7,8,12B HEXAHYDRO 7 METHYLINDOLO[4,3 AB]PHENANTHRIDINE; APOMORPHINE; BROMOCRIPTINE; CABERGOLINE; CATECHOL METHYLTRANSFERASE INHIBITOR; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; LISURIDE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NAXAGOLIDE; NEUROPROTECTIVE AGENT; QUINPIROLE; ROPINIROLE; SELEGILINE;

CELL COMMUNICATION; CONFERENCE PAPER; DISEASE SEVERITY; DOPAMINE BRAIN LEVEL; DOPAMINERGIC SYSTEM; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG INDUCED DISEASE; DYSKINESIA; HUMAN; NERVE CELL; NEUROPROTECTION; PARKINSON DISEASE; PRIORITY JOURNAL;

DOPAMINE AGENTS; DYSKINESIA, DRUG-INDUCED; HUMANS; LEVODOPA; PARKINSON DISEASE;

EID: 0034069554     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (112)

1. Marsden CD, Parkes JD. 'On-off' effects in patients with Parkinson's disease on chronic levodopa therapy. Lancet 1976;i:292-296
2. Fahn S. Adverse effects of levodopa. In: Olanow CW, Lieberman AN, eds. The scientific basis for the treatment of Parkinson's disease. Lancs, UK: Parthenon Publishing Group, 1992:89-112
3. Hauser RA, Olanow CW. Oro-buccal dyskinesia associated with trihexyphenidyl therapy in a patient with Parkinson's disease. Mov Disord 1993;8:512-514
4. Olanow CW, Fahn S, Muenter M, et al. A multi-center, double-blind, placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson's disease. Mov Disord 1994;9:40-47
5. Rascol O. Medical treatment of levodopa-induced dyskinesias. Ann Neurol 2000;47(suppl 1):S179-S188
6. Lang AE, Lozano AM, Montgomery E, et al. Posteroventral medial pallidotomy in advanced Parkinson's disease. N Engl J Med 1997;337:1036-1042
7. Olanow CW, Freeman TB, Kordower JH. Fetal nigral transplantation as a therapy for Parkinson's disease. Trends Neurosci 1996;19:102-109
8. Pahwa R, Wilkinson S, Smith D, et al. High-frequency stimulation of the globus pallidus for the treatment of Parkinson's disease. Neurology 1997;49:249-253
9. Limousine P, Krack P, Pollak P, et al. Electrical stimulation of the subthalamic nucleus in advanced Parkinson's disease. N Engl J Med 1998;339:1105-1111
10. Obeso JA, Grandas F, Vaamonde J, et al. Motor complications associated with chronic levodopa therapy in Parkinson's disease. Neurology 1989;39(Suppl 2):11-19
11. Lhermite F, Agid Y, Signoret JL. Onset and end-of-dose levodopa-induced dyskinesias. Arch Neurol 1978;35:261-262
12. Fahn S. Fluctuations of disability in Parkinson's disease: pathophysiology. In: Marsden CD, Fahn S, eds. Movement disorders. London: Butterworth, 1982:123-145
13. Albin RL, Young AB, Penney JB. The functional anatomy of basal ganglia disorders. Trends Neurosci 1989;12:366-375
14. DeLong MR. Primate models of movement disorders of basal ganglia origin. Trends Neurosci 1990;13:281-289
15. Filion M, Tremblay L. Abnormal spontaneous activity of globus pallidus neurons in monkeys with MPTP-induced parkinsonism. Brain Res 1991;547:142-151
16. Matsumura M, Tremblay L, Richard H, Filion M. Activity of pallidal neurons in the monkey during dyskinesia induced by injection of bicuculline in the external pallidum. Neuroscience 1995;65:59-70
17. Merello M, Balej J, Delfino M, et al. Apomorphine induces changes in GPi spontaneous outflow in patients with Parkinson's disease. Mov Disord 1999;14:45-49
18. Hutchison WD, Levy R, Dostrovsky JO, et al. Effects of apomorphine on globus pallidus neurons in Parkinsonian patients. Ann Neurol 1997;42:767-775
19. Obeso JA, Rodriguez MC, DeLong MR. Basal ganglia pathophysiology: a critical review. Adv Neurol 1997;74:3-18
20. Lee T, Seeman P, Rajput A, et al. Receptor basis for dopaminergic supersensitivity in Parkinson's disease. Nature 1978;273:59-61
21. Cortes R, Camps M, Gueye B, et al. Dopamine receptors in human brain: autoradiographic distribution of D1 and D2 sites in Parkinson syndrome of different etiology. Brain Res 1989;483:30-38
22. Olanow CW. A rationale for using dopamine agonists as primary symptomatic therapy in Parkinson's disease. In: Olanow CW, Obeso JA, eds. Dopamine agonists in early Parkinson's disease. Kent, UK: Wells Medical Publishing, 1997:37-48
23. Chase TN, Baronti F, Fabbrini G, et al. Rationale for continuous dopamimetic therapy of Parkinson's disease. Neurology 1989;39(Suppl 2):7-10
24. Obeso JA, Grandas FA, Herrero MT, Horowski R. The role of pulsatile versus continuous dopamine stimulation for functional recovery in Parkinson's disease. Eur J Neurosci 1994;6:889-897
25. Bédard PJ, Gomez-Mancilla B, Blanchet P. Dopamine agonists as first therapy of parkinsonism in MPTP monkeys. In: Olanow CW, Obeso JA, eds. Dopamine agonists in early Parkinson's disease. Kent, UK: Wells Medical Publishing, 1997:101-110
26. Bédard PJ, Di Paolo T, Falardeau P, Boucher R. Chronic treatment with levodopa, but not bromocriptine, induces dyskinesias in MPTP-parkinsonian monkeys: correlation with 3-H-spiperone binding. Brain Res 1986;379:294-299
27. Pearce RKB, Banerji T, Jenner P, Marsden CD. Effects of repeated treatment with L-dopa, bromocriptine and ropinirole in drug-naive MPTP-treated common marmosets [abstract]. Br J Pharmacol 1996;118:37
28. Falardeau P, Bouchard S, Bédard PJ, et al. Behavioural and biochemical effect of chronic treatment with D1 and/or D2 dopamine agonists in MPTP monkeys. Eur J Pharmacol 1988;150:59-66
29. Gagnon C, Bédard PJ, Di Paolo T. Effect of chronic treatment of MPTP monkeys with dopamine D-1 and/or D-2 receptor agonists. Eur J Pharmacol 1990;178:115-120
30. Luquin MR, Laguna J, Obeso JA. Selective D-2 receptor stimulation induces dyskinesias in parkinsonian monkeys. Ann Neurol 1992;31:551-554
31. Gomez-Mancilla B, Bédard PJ. Effect of chronic treatment with (+)-PHNO, a D2 agonist in MPTP-treated monkeys. Exp Neurol 1992;117:185-188
32. Gomez-Mancilla B, Bédard PJ. Effects of D1 and D2 agonists and antagonists on dyskinesia produced by levodopa in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treated monkeys. J Pharmacol Exp Ther 1991;259:409-413
33. Blanchet PJ, Bédard PJ, Britton DR, Kebabian JW. Differential effect of selective D1 and D2 dopamine receptor agonists on levodopa-induced dyskinesia in MPTP monkeys. J Pharmacol Exp Ther 1993;267:275-279
34. Mouradian MM, Heuser IJE, Baronti E, Chase NT. Modification of central dopaminergic mechanisms by continous levodopa therapy for advanced Parkinson's disease. Ann Neurol 1990;27:18-23
35. Vaamonde J, Luquin MR, Obeso JA. Dopaminergic responsiveness to apomorphine after chronic treatment with subcutaneous lisuride infusion in Parkinson's disease. Mov Disord 1990;5:260-262
36. Blanchet PJ, Calon F, Martel JC, et al. Continuous administration decreases and pulsatile administration increases behavioral sensitivity to a novel dopamine D2 agonist (U-91356A) in MPTP-exposed monkeys. J Pharmacol Exp Ther 1995;272:854-859
37. Fearnley JM, Lees AJ. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 1991;114:2283-2301
38. 18F]dopa-PET and clinical study of the rate of progression in Parkinson's disease. Brain 1996;119:585-591
39. Vingerhoets FJG, Snow BJ, Lee CS, et al. Longitudinal fluorodopa positron emission tomographic studies of the evolution of idiopathic parkinsonism. Ann Neurol 1994;36:759-764
40. Fabbrini G, Mouradian MM, Juncos JL, et al. Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms. Part I. Ann Neurol 1987;24:475-479
41. Olanow CW, Gauger LL, Cedarbaum J. Temporal relationships between plasma and CSF pharmacokinetics of levodopa and clinical effect in Parkinson's disease. Ann Neurol 1991;29:556-559
42. Wooten GF. Progress in understanding the pathophysiology of treatment-related fluctuations in Parkinson's disease. Ann Neurol 1987;24:366-371
43. Pearce RKB, Zeng BY, Jenner P, Marsden CD. Altered striatal preproenkephalin mRNA levels in normal macaque monkeys (Macaca fascicularis) with dyskinesias induced by chronic L-dopa administration [abstract]. Br J Pharmacol 1995;116:78
44. Calon F, Grondin R, Morisette M, et al. Molecular basis of levodopa-induced dyskinesias. Ann Neurol 2000;47(suppl 1):S70-S78
45. Canales JJ, Graybiel AM. Patterns of gene expression and behavior induced by chronic dopamine treatments. Ann Neurol 2000;47(suppl 1):S53-S59
46. Sheng M, Greenberg ME. The regulation and function of c-fos and other immediate early genes in the nervous system. Neuron 1990;4:477-485
47. Morgan JI, Curran T. Stimulus-transcription coupling in the nervous system: involvement of the inducible proto-oncogenes fos and jun. Annu Rev Neurosci 1991;14:421-451
48. Gerfen GR, Engber TM, Mahan LC, et al. D1 and D2 dopamine receptor mediated regulation of gene expression in striatonigral and striatopallidal pathways. Science 1990;250:1429-1432
49. Young WS III, Bonner TI, Brann MR. Mesencephalic dopaminergic neurons regulate the expression of neuropeptide mRNAs in the rat forebrain. Proc Natl Acad Sci USA 1986;83:9827-9831
50. Herrero MT, Augood SJ, Hirsch EC, et al. Effects of L-dopa in preproenkephalin and preprotachykinin gene expression in the MPTP-treated monkey striatum. Neuroscience 1995;68:1189-1198
51. Morissette M, Goulet M, Soghomonian JJ, et al. Preproenkephalin mRNA expression in the caudate-putamen of MPTP monkeys after chronic treatment with the D2 agonist U91356A in continuous or intermittent mode of administration: comparison with L-dopa therapy. Brain Res Mol Brain Res 1997;49:55-62
52. Jolkkonen J, Jenner P, Marsden CD. L-Dopa reverses altered gene expression of substance P but not enkephalin in the caudate-putamen of common marmosets treated with MPTP. Brain Res Mol Brain Res 1995;32:297-307
53. Morissette M, Goulet M, Soghomonian JJ, et al. Preproenkephalin mRNA expression in the caudate-putamen of MPTP monkeys after chronic treatment with the D2 agonist U91356A in continuous or intermittent mode of administration: comparison with L-dopa therapy. Brain Res Mol Brain Res 1997;49:55-62
54. Morissette M, Grondin R, Goulet M, et al. Differential regulation of striatal preproenkephalin and preprotachykinin mRNA levels in MPTP-lesioned monkeys chronically treated with dopamine D1 or D2 receptor agonists. J Neurochem 1999;72:682-692
55. Gerfen CR, Keefe KA, Gauda EB. D1 and D2 dopamine receptor function in the striatum: co-activation of D1- and D2-dopamine receptors on separate populations of neurons results in potentiated immediate early gene response in D1-containing neurons. J Neurosci 1995;15:8167-8176
56. Kato M, Kimura M. Effects of reversible blockade of basal ganglia on a voluntary arm movement. J Neurophysiol 1992;68:1516-1534
57. Burbaud P, Bonnet B, Guehl D, et al. Movement disorders induced by gamma-aminobutyric agonist and antagonist injections into the internal globus pallidus and substantia nigra pars reticulata of the monkey. Brain Res 1998;780:102-107
58. Hamada I, DeLong MR. Excitotoxic acid lesions of the primate subthalamic nucleus result in transient dyskinesias of the contralateral limbs. J Neurophysiol 1992;68:1850-1858
59. Hamada I, DeLong MR. Excitotoxic acid lesions of the primate subthalamic nucleus result in reduced pallidal neuronal activity during active holding. J Neurophysiol 1992;68:1859-1866
60. Filion M, Tremblay L, Bédard PJ. Effects of dopamine agonists on the spontaneous activity of globus pallidus neurons in monkeys with MPTP-induced parkinsonism. Brain Res 1991;547:152-161
61. Lozano AM, Lang AE, Levy R et al. Neuronal recordings in PD patients with dyskinesias induced by apomorphine. Ann Neurol 2000;47(suppl 1):S141-S146
62. Mitchell IJ, Boyce S, Sambrook MA, Crossman AR. A 2-deoxyglucose study of the effects of dopamine agonists on the parkinsonian primate brain. Implications for the neural mechanisms that mediate dopamine agonist-induced dyskinesia. Brain 1992;115:809-824
63. Marsden CD, Obeso JA. The functions of the basal ganglia and the paradox of stereotactic surgery for Parkinson's disease. Brain 1994;117:877-897
64. Herrero MT, Levy R, Ruberg M, et al. Consequence of nigrostriatal denervation and L-dopa therapy on the expression of glutamic acid decarboxylase (GAD) messenger RNA in the pallidum. Neurology 1996;47:219-224
65. Vila M, Levy R, Herrero MT, et al. Consequences of nigrostriatal denervation on the functioning of the basal ganglia in human and nonhuman primates: an in situ hybridization study of cytochrome oxidase subunit I mRNA. J Neurosci 1997;17:765-773
66. Crossman AR. Primate models of dyskinesias: the experimental approach to the study of basal ganglia related involuntary movement disorders. Neuroscience 1987;21:1-40
67. Calabresi P, Pisani A, Mercuri NB, Bernardi G. The corticostriatal projection: from synaptic plasticity to dysfunctions of the basal ganglia. Trends Neurosci 1996;19:19-24
68. Calabresi P, Mai R, Mercuri NB, Bernardi G. Coactivation of D1 and D2 dopamine receptors is required for long-term synaptic depression in the striatum. Neurosci Lett 1992;142:95-99
69. Calabresi P, Giacomini P, Bernardi G. Levodopa-induced dyskinesia: a pathological form of striatal synaptic plasticity? Ann Neurol 2000;47(suppl 1):S60-S69
70. Yoshida M. The neuronal mechanism underlying parkinsonism and dyskinesia: differential roles of the putamen and caudate nucleus. Neurosci Res 1991;12:31-40
71. Filion M. Physiologic basis of dyskinesia. Ann Neurol 2000; 47(suppl 1):S35-S41
72. Jenner P, Tulloch I. The preclinical pharmacology of ropini-role-receptor interactions, antiparkinsonian activity and potential to induce dyskinesia. In: Olanow CW, Obeso JA, eds. Beyond the decade of the brain, Vol. 2: Dopamine agonists in early Parkinson's disease. Royal Tunbridge Wells: Wells Medical Limited, 1997:115-128.
73. Rascol A, Guiraud B, Montrastruc JL, et al. Long-term treatment of Parkinson's disease with bromocriptine. J Neurol Neurosurg Psychiatry 1979;42:143-150
74. Lees AJ, Stern GM. Sustained bromocriptine therapy in previously untreated patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 1981;44:1021-1023
75. Rinne UK. Combined bromocriptine levodopa therapy early in Parkinson's disease. Neurology 1985;35:1196-1198
76. Rinne UK. Early combination of bromocriptine and levodopa in the treatment of Parkinson's disease: a 5 year follow-up. Neurology 1987;37:826-828
77. Montastruc JL, Rascol O, Senard JM, Rascol A. A randomized controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: a five year follow up. J Neurol Neurosurg Psychiatry 1994;57:1034-1038
78. Olanow CW, Alberts M, Stajich J, Burch G. A randomized blinded study of low dose bromocriptine versus low dose carbidopa/levodopa in untreated Parkinson patients. In: Fahn S, Marsden D, Calne D, Goldstein M, eds. Recent developments in Parkinsons disease, Vol II. Florham Park, NJ: Macmillan Healthcare Information, 1987:201-208
79. Bloch G, Liss G, Reiner S, et al. Comparison of immediate-release and controlled-release carbidopa-levodopa in Parkinson's disease. Eur Neurol 1997;37:23-27
80. Marsden CD, Olanow CW. Neuroprotection in Parkinson's disease: the causes of Parkinson's disease are being unravelled and rational neuroprotective therapy is close to reality. Ann Neurol 1998;44:189-196
81. Parkinson's Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1993;328:176-183
82. Olanow CW, Hauser RA, Gauger L, et al. The effect of deprenyl and levodopa on the progression of signs and symptoms in Parkinson's disease. Ann Neurol 1995;38:771-777
83. Olanow CW, Mytilineou C, Tatton WH. Status of selegiline as a neuroprotective agent in Parkinson's disease. Mov Disord 1998;13:55-58
84. Tatton NA, Maclean-Fraser A, Tatton WG, et al. A fluorescent double-labeling method to detect and confirm apoptotic nuclei in Parkinson's disease. Ann Neurol 1998;44:142-148
85. Myllyla VV, Sotaniemi KA, Hakulinen P, et al. Selegiline as the primary treatment of Parkinson's disease - a long term double blind study. Acta Neurol Scand 1997;95:211-228
86. Parkinson's Study Group. The impact of deprenyl and tocopherol treatment in Parkinson's disease patients requiring levodopa. Ann Neurol 1996;39:37-45
87. Olanow CW, Jenner P, Brooks D. Dopamine agonists and neuroprotection in Parkinson's disease. Ann Neurol 1998;44:167-174
88. Carter AJ, Muller RE. Pramipexole, a dopamine D2 receptor agonist, decreases the extracellular concentration of dopamine in vivo. Eur J Pharmacol 1991;200:65-72
89. Nishibayashi S, Asanuma M, Kohno M, et al. Scavenging effects of dopamine agonists on nitric oxide radicals. J Neurochem 1996;67:2208-2211
90. Gassen M, Glinka Y, Pinchasi B, Youdim MB. Apomorphine is a highly potent free radical scavenger in rat brain mitochondrial fraction. Eur J Pharmacol 1996;308:219-225
91. Yoshikawa T, Minamiyama Y, Naito Y, et al. Antioxidant properties of bromocriptine, a dopamine agonist. J Neurochem 1994;62:1034-1038
92. Carvey PM, Pieri S, Ling ZD. Attenuation of levodopa-induced toxicity in mesencephalic cultures by pramipexole. J Neural Transm 1997;104:209-228
93. Sawada H, Ibi M, Kihara T, et al. Dopamine D2-type agonists protect mesencephalic neurons from glutamate neurotoxicity: mechanisms of neuroprotective treatment against oxidative stress. Ann Neurol 1998;44:110-119
94. 2 and 6-hydroxydopamine. Mov Disord 1998;13:661-667
95. Ogawa N, Tanaka K, Asanuma M, et al. Bromocriptine protects mice against 6-hydroxydopamine and scavenges hydroxyl free radical in vitro. Brain Res 1994;657:207-213
96. Felten DL, Felten SY, Fuller RW, et al. Chronic dietary pergolide preserves nigrostriatal neuronal integrity in aged Fischer 344 rats. Neurobiol Aging 1992;13:339-351
97. Rodriguez MC, Obeso JA, Olanow WC. Subthalamic nucleus mediated excitotoxicity in Parkinson's disease: a target for neuroprotection. Ann Neurol 1998;44(Suppl 1):175-188
98. Van Blercom N, Charles D, Limousin P, et al. Long-term bilateral subthalamic nucleus stimulation for the treatment of Parkinson's disease. Neurology 1999;52(6 Suppl 2):A271 (Abstract)
99. Turski L, Bressler K, Rettig KJ, et al. Protection of substantia nigra from MPP+ neurotoxicity by N-methyl-D-aspartate antagonists. Nature 1991;349:414-418
100. Barneoud P, Mazadier M, Miquet J-M, et al. Neuroprotcctive effects of riluzole on a model of Parkinson's disease in the rat. Neuroscience 1996;74:971-983
101. Boireau A, Dubedat P, Bordier F, et al. Riluzole and experimental parkinsonism: antagonism of MPTP-induced decrease in central dopamine levels in mice. Neuroreport 1994;5:2657-2660
102. Piallat B, Bennazzouz A, Benabid AL. Subthalamic nucleus lesion on rats prevents dopaminergic nigral neuron degeneration after striatal 6-OH-DA injection: behavioural and immunohistochemical studies. Eur J Neurosci 1996;8:1408-1414
103. Freeman TB, Olanow CW, Hauser RA, et al. Bilateral fetal nigral transplantation into the postcommissural putamen in Parkinson's disease. Ann Neurol 1995;38:379-388
104. Kordower JH, Freeman TB, Snow BJ, et al. Post mortem evidence of dopamine graft survival and striatal reinnervation in a Parkinson's disease patient displaying improved motor function following fetal nigral transplantation. N Engl J Med 1995;332:1118-1124
105. Kordower JH, Rosenstein JM, Collier TM, et al. Functional fetal nigral grafts in a patient with Parkinson's disease: chemoanatomic, quantitative, ultrastructural, and metabolic studies. J Cardiovasc Nurs 1996;370:203-230
106. Freed CR, Breeze RE, Greene PE, et al. Double-blind controlled trial of human embryonic dopamine cell transplants in advanced Parkinson's disease: study design, surgical strategy, patient demographics, and pathological outcome [abstract]. Neurology 1999;52(6 Suppl 2):A272
107. Chase TH, Oh JD. Striatal mechanisms and pathogenesis or parkinsonian signs and motor complications. Ann Neurol 2000;47(suppl 1):S122-S130
108. Papa SM, Chase TN. Levodopa-induced dyskinesias improved by a glutamate antagonist in Parkinsonian monkeys. Ann Neurol 1996;39:574-578
109. Verhagen Metman L, Del Dotto P, Natte R, et al. Dextromethorphan improves levodopa-induced dyskinesias in Parkinson's disease. Neurology 1998;51:203-206
110. Verhagen Metman L, Del Dotto P, van den Munckhof P, et al. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Neurology 1998;50:1323-1326
111. Olanow CW, Koller WC. An algorithm (decision tree) for the management of Parkinson's disease: treatment guidelines. American Academy of Neurology. Neurology 1998;50(3 Suppl 3):S1-S57
112. Rascol O. A double blind L-dopa controlled study of ropinirole in de novo patients with Parkinson's disease [abstract]. Neurology 1996;46:A160